trichostatin A

Trichostatin is a lipid of Polyketides (PK) class. Trichostatin is associated with abnormalities such as Dentatorubral-Pallidoluysian Atrophy, PARAGANGLIOMAS 3, abnormal fragmented structure, Disintegration (morphologic abnormality) and Hyperostosis, Diffuse Idiopathic Skeletal. The involved functions are known as Acetylation, Cell Differentiation process, histone modification, Gene Silencing and Transcriptional Activation. Trichostatin often locates in CD41a, Hematopoietic System, Chromatin Structure, Blood and Endothelium. The associated genes with Trichostatin are SPI1 gene, CELL Gene, Chromatin, CXCR4 gene and DNMT1 gene. The related lipids are Butyrates, Promega, butyrate, Lipopolysaccharides and Steroids. The related experimental models are Knock-out, Mouse Model, Xenograft Model and Cancer Model.

Cross Reference

Introduction

To understand associated biological information of trichostatin A, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with trichostatin A?

trichostatin A is suspected in Infection, Morphologically altered structure, Ureteral obstruction, Photosensitization, Atherosclerosis, Hypertrophic Cardiomyopathy and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with trichostatin A

MeSH term MeSH ID Detail
Osteoarthritis, Knee D020370 13 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Neoplasms D009369 13 associated lipids
Intellectual Disability D008607 13 associated lipids
Radiation Injuries D011832 14 associated lipids
Brain Neoplasms D001932 15 associated lipids
Tongue Neoplasms D014062 15 associated lipids
Uterine Neoplasms D014594 18 associated lipids
Carcinoma D002277 18 associated lipids
Leukemia, Myeloid, Acute D015470 19 associated lipids
Per page 10 20 50 100 | Total 139

PubChem Associated disorders and diseases

What pathways are associated with trichostatin A

Lipid pathways are not clear in current pathway databases. We organized associated pathways with trichostatin A through full-text articles, including metabolic pathways or pathways of biological mechanisms.

Related references are published most in these journals:

Pathway name Related literatures
Loading... please refresh the page if content is not showing up.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with trichostatin A?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with trichostatin A?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with trichostatin A?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with trichostatin A?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with trichostatin A?

Mouse Model

Mouse Model are used in the study 'Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer.' (Majid S et al., 2010), Mouse Model are used in the study 'Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.' (Fang MZ et al., 2005) and Mouse Model are used in the study 'Histone deacetylase 3 mediates allergic skin inflammation by regulating expression of MCP1 protein.' (Kim Y et al., 2012).

Xenograft Model

Xenograft Model are used in the study 'Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.' (Landreville S et al., 2012), Xenograft Model are used in the study 'Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells.' (Moiseeva EP et al., 2007) and Xenograft Model are used in the study 'Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.' (Touma SE et al., 2005).

Cancer Model

Cancer Model are used in the study 'Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice.' (Sanderson L et al., 2004).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with trichostatin A

Download all related citations
Per page 10 20 50 100 | Total 3126
Authors Title Published Journal PubMed Link
Luo W et al. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. 2010 Cancer Res. pmid:20587525
Mariadason JM et al. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. 2000 Cancer Res. pmid:10969808
Terui T et al. Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. 2003 Cancer Res. pmid:14695212
Shah S et al. Targeting pioneering factor and hormone receptor cooperative pathways to suppress tumor progression. 2012 Cancer Res. pmid:22258452
Shi J et al. Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. 2007 Cancer Res. pmid:17616702
Sugita K et al. Morphological reversion of sis-transformed NIH3T3 cells by trichostatin A. 1992 Cancer Res. pmid:1727377
Yoshida M et al. Effects of trichostatins on differentiation of murine erythroleukemia cells. 1987 Cancer Res. pmid:2439196
Sirchia SM et al. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. 2002 Cancer Res. pmid:11980632
Kretzner L et al. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. 2011 Cancer Res. pmid:21502403
Harada K et al. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. 2002 Cancer Res. pmid:12384554
Ho WC et al. Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells. 2005 Cancer Res. pmid:15899819
Tran T et al. Enhancement of folate receptor alpha expression in tumor cells through the glucocorticoid receptor: a promising means to improved tumor detection and targeting. 2005 Cancer Res. pmid:15899836
Liu LT et al. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. 2003 Cancer Res. pmid:12810630
Allison SJ and Milner J Loss of p53 has site-specific effects on histone H3 modification, including serine 10 phosphorylation important for maintenance of ploidy. 2003 Cancer Res. pmid:14583461
Lin YC et al. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. 2008 Cancer Res. pmid:18381445
Wang J et al. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. 1999 Cancer Res. pmid:10383127
Zhao S et al. Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells. 2003 Cancer Res. pmid:12750289
Stiehl DP et al. Histone deacetylase inhibitors synergize p300 autoacetylation that regulates its transactivation activity and complex formation. 2007 Cancer Res. pmid:17332356
Mori T et al. Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. 2005 Cancer Res. pmid:15753377
Nervi C et al. Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity. 2001 Cancer Res. pmid:11245412
Zhu WG et al. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. 2001 Cancer Res. pmid:11245429
Mizutani H et al. Romidepsin (FK228), a potent histone deacetylase inhibitor, induces apoptosis through the generation of hydrogen peroxide. 2010 Cancer Sci. pmid:20624163
Sakuma M et al. Promoter methylation status of the Cyclin D2 gene is associated with poor prognosis in human epithelial ovarian cancer. 2007 Cancer Sci. pmid:17270028
Tomosugi M et al. Retinoblastoma gene-independent G1 phase arrest by flavone, phosphatidylinositol 3-kinase inhibitor, and histone deacetylase inhibitor. 2012 Cancer Sci. pmid:22957647
Chikamatsu K et al. Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck. 2013 Cancer Sci. pmid:23992541
Hattori N et al. Methylation silencing of angiopoietin-like 4 in rat and human mammary carcinomas. 2011 Cancer Sci. pmid:21489049
Sasaki K et al. Histone deacetylase inhibitors trichostatin A and valproic acid circumvent apoptosis in human leukemic cells expressing the RUNX1 chimera. 2008 Cancer Sci. pmid:18271940
Furumai R et al. Histone deacetylase inhibitors block nuclear factor-κB-dependent transcription by interfering with RNA polymerase II recruitment. 2011 Cancer Sci. pmid:21299717
Yamada Y et al. Aberrant methylation of the vascular endothelial growth factor receptor-1 gene in prostate cancer. 2003 Cancer Sci. pmid:12824880
Okada T et al. Identification of genes specifically methylated in Epstein-Barr virus-associated gastric carcinomas. 2013 Cancer Sci. pmid:23829175
Akao Y et al. Downregulation of microRNAs-143 and -145 in B-cell malignancies. 2007 Cancer Sci. pmid:17892514
Leng SL et al. Insulin-like growth factor-II renders LIM 2405 human colon cancer cells resistant to butyrate-induced apoptosis: a potential mechanism for colon cancer cell survival in vivo. 2001 Carcinogenesis pmid:11577001
Ma J et al. Promoter hypermethylation and histone hypoacetylation contribute to pancreatic-duodenal homeobox 1 silencing in gastric cancer. 2010 Carcinogenesis pmid:20622005
Kim YH et al. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. 2004 Carcinogenesis pmid:15142888
Gastaldi T et al. Plakoglobin is differentially expressed in alveolar and embryonal rhabdomyosarcoma and is regulated by DNA methylation and histone acetylation. 2006 Carcinogenesis pmid:16537559
Grassi G et al. Inhibitors of DNA methylation and histone deacetylation activate cytomegalovirus promoter-controlled reporter gene expression in human glioblastoma cell line U87. 2003 Carcinogenesis pmid:12869421
Kwon O et al. NF-kappaB inhibition increases chemosensitivity to trichostatin A-induced cell death of Ki-Ras-transformed human prostate epithelial cells. 2006 Carcinogenesis pmid:16774937
Chen CQ et al. Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class I histone deacetylases. 2013 Carcinogenesis pmid:23430957
Thakur VS et al. Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases. 2012 Carcinogenesis pmid:22114073
Sharma A et al. Trichostatin-A modulates claudin-1 mRNA stability through the modulation of Hu antigen R and tristetraprolin in colon cancer cells. 2013 Carcinogenesis pmid:23880304
Derks S et al. Promoter CpG island hypermethylation- and H3K9me3 and H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal region 18q21. 2009 Carcinogenesis pmid:19329758
Jensen TJ et al. Epigenetic remodeling during arsenical-induced malignant transformation. 2008 Carcinogenesis pmid:18448484
Bhakat KK and Mitra S CpG methylation-dependent repression of the human O6-methylguanine-DNA methyltransferase gene linked to chromatin structure alteration. 2003 Carcinogenesis pmid:12807730
Xiang N et al. Selenite reactivates silenced genes by modifying DNA methylation and histones in prostate cancer cells. 2008 Carcinogenesis pmid:18676679
Nandakumar V et al. (-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells. 2011 Carcinogenesis pmid:21209038
Liu T et al. Regulation of Cdx2 expression by promoter methylation, and effects of Cdx2 transfection on morphology and gene expression of human esophageal epithelial cells. 2007 Carcinogenesis pmid:16990345
Kamitani H et al. Expression of 15-lipoxygenase-1 is regulated by histone acetylation in human colorectal carcinoma. 2001 Carcinogenesis pmid:11159758
Kaichi S et al. Cell line-dependent differentiation of induced pluripotent stem cells into cardiomyocytes in mice. 2010 Cardiovasc. Res. pmid:20547733
Becker JR et al. In vivo natriuretic peptide reporter assay identifies chemical modifiers of hypertrophic cardiomyopathy signalling. 2012 Cardiovasc. Res. pmid:22198505
Chahine MN et al. Nuclear pore rearrangements and nuclear trafficking in cardiomyocytes from rat and human failing hearts. 2015 Cardiovasc. Res. pmid:25341891